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Abstract
Background: Glomerular filtration rate (GFR) is considered as a gold standard of kidney func-
tion. However, using GFR as the gold standard is not common in clinical practice, because its 
direct measurement is usually expensive, cumbersome, and invasive. In the present study, we 
assessed the predictive power of two other biomarkers, Cystatin-C (Cys-C) and Neutrophil 
Gelatinase-Associated Lipocalin (NGAL) for early detection of chronic kidney diseases (CKD) 
in the absence of a gold standard. Materials and Methods: In this study, 72 patients who re-
ferred to the Shohadaye Tajrish Hospital of Tehran, Iran, for measuring their kidney function 
were studied. The ELISA method was utilized for measuring plasma NGAL (PNGAL) and 
serum Cys-C (SCys-C). The Bayesian latent class modeling approach was applied to asses the 
predictive power of these biomarkers. Results: While both the biomarkers had rather high sen-
sitivities (PNGAL=91%, SCys-C= 89%), the specificity of SCys-C biomarker was very lower 
than the one of PNGAL (SCys-C=56%, PNGAL=94%). The estimated area under the receiv-
er operating characteristic (ROC) curve for SCys-C as the single biomarker for the diagnosis 
of CKD was about 0.76, while a similar estimate for PNGAL was 0.93. The added value of 
PNGAL to SCys-C for the diagnosis of CKD in terms of the ROC curve was about 0.19, while 
the added value of SCys-C to PNGAL was less than 0.02. Conclusion: In general, our findings 
suggest that PNGAL can be utilized as a single reliable biomarker for early detection of CKD. 
In addition, results showed that when a perfect gold standard is not available, Bayesian ap-
proaches to latent class models could lead to more precise sensitivity and specificity estimates 
of imperfect tests. [GMJ.2020;9:e1698] DOI:10.31661/gmj.v9i0.1698
Keywords: Chronic Kidney Diseases; Neutrophil Gelatinase-Associated Lipocalin; Cystatin C; 
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Introduction
Chronic kidney disease (CKD) is one of the most prevalent problems of the uri-
nary tract system. This problem is usually de-
fined as abnormalities of kidney structure of 
function present for more than three months 
[1]. CKD in its early stage is a silent problem 
and its symptoms are evident when patients 
reached end-stage renal failures [2]. Late 
detection of CKD causes incidence of other 
subsequent outcomes of the disease [3]. The 
incidence, prevalence, and global burden of 
CKD are increasing rapidly; recent reports 
show that the incidence rate of this disease 
in many parts of the world was over 200 per 
million individuals in 2012 [4], and the global 
prevalence rate is 14.3%  in the most popu-
lation [5]. CKD was ranked as 27th among 
causes of death in 1990, while it became as 
18th and 12th in  2010 and 2015, respectively 
[6]. Regarding increasing prevalence rate of 
CKD and its considerable burden throughout 
the world, early diagnostic and proper treat-
ment of this disease could help physicians to 
control the progress and improve the conse-
quences of the disease. In this context, iden-
tifying related indicators of CKD is of great 
importance for diagnosing this disease in its 
early stage. In the past decades, researchers 
have developed a variety of markers for eval-
uating kidney function. Among these markers, 
the glomerular filtration rate (GFR) is known 
as the most optimal index of kidney func-
tion because of its reduction after structural 
kidney damage. In CKD patients, it is also 
known that many other kidney functions de-
cline in parallel with GFR [7, 8]. According 
to 2009 Kidney Disease: Improving Global 
Outcomes (KDIGO) clinical practice guide-
line, the GFR of 90mL/min/1.73  represents 
healthy kidneys and the value less than 15 
mL/min/1.73  indicates the end stage of kid-
ney disease [9]. The GFR less than 60 mL/
min/1.73  for more than three months is the 
common threshold of CKD [10]. Since direct 
measurement of GFR is impossible, some al-
ternatives are instead utilized to measure the 
clearance of exogenous substances that elim-
inated by filtration only [11]. In this context, 
inulin clearance is widely used as a gold stan-
dard method to measure GFR [12]. However, 
the rigorous measurement of inulin clearance 
is invasive, cumbersome, and expensive be-
cause it needs continuous intravenous infu-
sion and repeated assessments of blood and 
urine [13]. Another common method for mea-
suring GFR is estimating its value using the 
formulas developed by the Modification of 
Diet in Renal Disease (MDRD) study group 
[14]. According to the MDRD, although, the 
eGFR is usually an acceptable approximation, 
like other creatinine-based approximations of 
GFR, it may lead to underestimated or overes-
timated results, for example in some ages or 
body mass index (BMI) groups [15]. Besides, 
among most commonly-used formulas, one 
of them was able to estimate the GFR using 
serum creatinine, age, race, and sex. In addi-
tion, another version of the MDRD formula 
applied six variables for estimating GFR. De-
spite all we have mentioned above, since lim-
ited accuracy and significant misclassification 
have been seen in the estimation of parame-
ters, the formulas cannot be considered as a 
proper method [16-18]. Because of problems 
with using creatinine-based estimates of GFR, 
researchers have recently developed some 
other alternatives for estimating GFR. Cys-
tatin –C (Cys-C) is one of these alternatives 
that is widely used as an indicator of kidney 
function [19]. Cys-C level in urine represents 
the overall function of kidney, so that an in-
crease in its concentration is related to a re-
duction in GFR. Unlike creatinine, Cys-C is 
independent of diet and muscle mass. These 
characteristic makes Cys-C a sensitive and 
popular indicator for estimating GFR [20]. 
Neutrophil Gelatinase- Associated Lipocalin 
(NGAL), also called lipocalin-2, is another 
well- known biomarker that is frequently re-
ported in the published literature as an early 
indicator of chronic kidney damage [21, 22]. 
This protein is expressed in neutrophils and 
low levels of it could be found in kidney, 
prostate, and alimentary and respiratory tracts 
[23]. In recent years, the predictive power of 
NGAL for early detection of kidney disease is 
explored in numerous studies [24-26]. In addi-
tion, some studies compared predictive power 
of NGAL with other biomarkers like Cys-C 
and creatinine, for early diagnosis of different 
renal diseases [26-28]. As mentioned before, 
several researchers have previously studied 
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the predictive power of Cys-C and NGAL 
biomarkers in the early detection of CKD. In 
the published literature, controversial findings 
have been reported about the sensitivity and 
specificity of the described biomarkers. In the 
present study, we follow two important ob-
jects. First, we aim to determine the predic-
tive power of Cys-C and NGAL biomarkers 
in the early detection of CKD using the com-
mon indices, i.e. sensitivity and specificity. 
Second, we estimate the added value of each 
biomarker to the other one. In other words, we 
aim to know whether adding the information 
from each biomarker to the other one leads to 
a significant increase in the accuracy of diag-
nosing CKD. To achieve these goals, we used 
a latent class model in the absence of the gold 
standard [29].
Materials and Methods
        
Study Population
In this cross-sectional study, patients who re-
ferred to the Shohadaye Tajrish hospital (af-
filiated to Shahid Beheshti University, Teh-
ran, Iran) for examining their kidney function 
were assayed. The Characteristics of the pa-
tients was shown in Table-1.
Inclusion and Exclusion Criteria
In this study, only patients with normal urea 
and creatinine were recruited. Patients with 
chronic cardiovascular and liver disease were 
not included in the study. The written study 
consent was obtained from each patient.
Data Collection
In this study, 10cc fasting blood sample was 
collected from each participant. Then, 5cc 
of this sample was used in tubes containing 
EDTA and plasma was immediately separated 
using a refrigerated centrifuge. The rest 5cc 
blood was collected in tubes without anticoag-
ulant. After 30 minutes, the coagulated blood 
was centrifuged to obtain the serum. The 
maintained serum and plasma were stored at 
-200c until the test day. The ELISA method 
was used for plasma NGAL (PNGAL) and se-
rum Cys-c (SCys-c) measurements.
Ethical Statements
This research has been approved by the Ethics 
Committee of the Shahid Beheshti University 
in Tehran, Iran (the ethical code: IR.SBMU.
RETECH.REC.1397.1182).
Statistical Analysis
In recent decades, a variety of statistical tools 
have been proposed by the data analysis for 
assessing the predictive power of multiple 
tests (biomarkers) for diagnosing disease with 
no gold standard. Among these methods, the 
Bayesian latent class models (BLCMs) inter-
esting approaches, which enable researches 
to combine the results of multiple tests (con-
sidering the conditional independence be-
tween tests) and predict the diagnostic power 
of these tests, in the absence of reliable gold 
standards. For two diagnostic tests, with di-
chotomous (binary) results, the latent class 
models can be written as:
p(T1+,T2+)=Π(sens1sens2)+(1-Π)(1-spec1)(1-
spec2)
p(T1-,T2+)=Π(sens2(1-sens1))+(1-Π)(spec1(1-
spec2 ))
p(T1-,T2-)=Π(1-sens1)(1-sens2)+(1-Π)(spec1 
spec2)
p(T1+,T2-)=Π(sens1(1-sens2))+(1-Π)(spec2(1-
spec1))
where Tj(j=1,2), sensj,specj and Π show jth 
Table l. Characteristics of the Patients
Characteristics Minimum Maximim Mean Standard Deviation
Age 40.00 70.00 54.50 8.06
Weight 49.00 113.00 79.28 13.65
Creatinine 0.70 1.40 1.02 0.17
Urea 11.00 45.00 27.10 8.40
Fibrinogen 146.00 345.00 215.80 66.40
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test, the sensitivity of jth test, specificity of jth 
test and disease prevalence, respectively. One 
of the most important aspects of this LCM is 
that when we apply model there is no need to 
consider any test as the gold standard and we 
can combine some imperfect diagnostic tests 
for obtaining unbiased estimators [29].  In this 
study, based on a non-parametric method, the 
amount of area under the receiver operating 
characteristic (ROC) curve (AUC) was calcu-
lated for, and then  (as a new test) was add-
ed to the model in the presence of  and the 
AUC was calculated. Finally, the difference 
between these two amounts showed that using 
can define the amount of the diagnostic accu-
racy increase. Also, Statistical analyses were 
performed using the WinBUGS for Windows, 
Version 1.4.3 that was developed by the MRC 
Biostatistics Unit, at the University of Cam-
bridge, United Kingdom and R 3.4.1 software.
Results
In this study, 72 patients (24 male and 48 fe-
male) who referred to the Shohadaye Tajrish 
hospital were investigated. The mean age of 
these patients was 54.50±8.06, ranged from 
40 to 70 years. Table-1 shows the descrip-
tive statistics for some characteristics of these 
patients.  The mean of SCys-C and PNGAL 
for these patients was 423.76±744.97 and 
78.73±105.44, respectively. According to the 
cut-off point value of 98 for SCys-C, 42 indi-
viduals (58.3%) had CKD. While, regarding 
the cut-off point value of 32 for PNGAL, 25 
persons (34.7%) were diagnosed as patients 
with CKD. Among these 72 patients, 24 per-
sons (33.3%) had SCys-C value higher than 
98 and PNGAL value higher than 32, concur-
rently (Table-2). In the next step of data anal-
ysis, we used two BLCMs. In model 1, we 
assessed the added value of  PNGAL (as the 
new test) to the SCys-C (as the current test) 
and in model 2 we evaluated the added value 
of SCys-C (as the new test) to the PNGAL (as 
the current test). Table-2 shows the obtained 
estimates from fitting these models. According 
to the estimates in Table-2, one can conclude 
that while both the biomarkers had rather 
high sensitivity (91% for PNGAL v.s 89% for 
SCys-C), the specificity of SCys-C biomarker 
was much lower than PNGAL (56% v.s 94%). 
Regarding the estimated AUCs from two mod-
els, some other interesting findings can be ob-
tained. The estimated AUC based on SCys-C 
as the single biomarker for diagnosing CKD 
was about 76%, while a similar estimate for 
PNGAL was 93%. It seems PNGAL can clas-
sify CKD more accurately than SCys-C. Fur-
thermore, the estimated AUC difference form 
two models tell us that the added value of 
PNGAL to SCys-C for diagnosing CKD was 
about 19%, while the added value of SCys-C 
to PNGAL was less than 2%.
Discussion
CKD, as an important risk indicator of car-
diovascular disease, is a major health prob-
lem throughout the world. The prevalence 
and incidence estimate of this disease is rather 
vague because it is commonly undetectable 
Table 2. Accuracy of SCys-C and PNGAL for Diagnosing CKD Using BLCM
Accuracy Index Model 1 Model 2
PNGAL Sensitivity 0.91(0.87,0.95)* 0.91(0.87,0.95)
PNGAL Specificity 0.94(0.90,0.98) 0.94(0.90,0.98)
SCys-C Sensitivity 0.89(0.85,0.93) 0.89(0.85,0.93)
SCys-C Specificity 0.56(0.5,0.62) 0.56(0.5,0.62)
SCys-C AUC 0.76 (0.74,0.78) -----
PNGAL AUC ----- 0.93(0.89,0.97)
SCys-C & NGAL AUC 0.95(0.92,0.98) 0.95(0.92,0.98)
AUC Difference 0.19**(0.17,0.21) 0.02***(0.004,0.04)
* (95% CI)
**Added value of PNGAL to Cys-C
***Added Value of Cys-C to NGAL
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and asymptomatic in the early stages. The di-
agnosis of CKD in the later stages imposes a 
high economic cost to the health systems of 
all world countries annually. Regarding this 
global health burden, identifying relevant bio-
markers for detecting CKD in the early stag-
es is of great importance. In this research, we 
assessed the power of two well-known bio-
markers for early diagnosis of CKD [30]. In 
previous decades, creatinine has been widely 
used as a common marker for detecting CKD. 
However, its late response to changes in the 
structure and function of the kidney encour-
aged researchers to identify other biomarkers 
such as Cys-C for early diagnostic of CKD 
[19]. In this context, Yilmaz et al. conducted 
a study on 26 patients with renal failure (stage 
1-4) in order to assess the role of Cys-C in 
diagnosing CKD. Their results demonstrated 
that Cys-C is an appropriate marker for es-
timating GFR with high accuracy (senseiv-
ity=92%, specificity=1) and detecting CKD 
in the early stages [31]. In the current study, 
we found that Cys-C has low power for detec-
tion of non-CKD patients (specificity=56%). 
It should be noted that high sensitivity and 
specificity in the study by Yilmaz et al. might 
not be precisely indicated the accuracy of the 
Cys-C marker, because the measurement er-
ror was not eliminated in their gold standard 
(eGFR) [18]. This could affect the sensitivi-
ty and specificity of Cys-C in their study. In 
addition, the aforementioned error in the gold 
standard may affect the correct diagnosis of 
the best cut-point for Cys-C. The results ob-
tained in our study were not in accordance 
with what they have achieved. This may be 
due to absence of gold standard in our work. 
On the other hand, the sample size used in the 
Yilmaz et al. study seems not to be adequate 
which makes the reported Sensitivity and 
specificity more questionable. NGAL has re-
cently been recognized as another appropriate 
marker for early diagnosis of CKD [24-26]. 
Increasing serum and urine levels of NGAL 
after kidney damage could be considered as 
an eligible marker for the early diagnosis of 
kidney damage [32, 33]. Moreover, the results 
of several related studies reported a significant 
correlation between NGAL, Cys-C, and GFR. 
Seems there is an agreement about the  NGAL 
as a  proper marker for early CKD detection 
[34, 35]. Basturk et al. used eGFR as the gold 
standard for early detection of CKD on 45 pa-
tients in stage 1 and reported a sensitivity and 
specificity of 72.2% by using an optimal cut-
point value of 98.71 ng/mL for NGAL. In our 
study, the sensitivity and specificity of NGAL 
for diagnosing CKD were 91% and 94%, re-
spectively. This notable difference may be at-
tributed to the error in the eGFR results that 
were used as the gold standard in the Basturk 
et al. study. In  Another conducted by Bolig-
nano et al. on 96 white European patients with 
various degrees of the renal disease, the eGFR 
was considered as the gold standard and the 
results showed that the accuracy of NGAL 
(sensitivity=83.9% and specificity=53.8%) 
for detecting CKD was notably lower than 
what we estimated in our study [35]. One rea-
son for this difference might be the presence 
of error measurement in the gold standard 
used in the Bolignano et al. study. This means 
that the use of inaccurate gold standard might 
be led to misleading estimates for sensitivity 
and specificity of a marker in the detection 
and diagnosis. In other words, estimating the 
sensitivity and specificity in the absence of a 
gold standard may lead to more accurate re-
sults than using a gold standard with possi-
ble measurement error. Similar to our work, 
some researchers have previously compared 
the accuracy of NGAL and Cys-C in the early 
detection of CKD. In a study by Mitsnefes et 
al.  in 2007 on 45 CKD patients aged 6 to 21 
years, the obtained results showed that adding 
NGAL to Cys-C might increase the diagnos-
tic accuracy by using GFR as the gold stan-
dard [34]. In another study, Gharishvandi et 
al.  used the cut point of 78mL/min/1.73 for 
eGFR as the gold standard and examined the 
diagnostic power of these two markers. Their 
findings indicate that PNGAL with sensitiv-
ity =96% and specificity=100% could have 
higher diagnostic power compared to Cys-C 
(sensitivity of 92% and specificity of 60 %) 
[25]. We found a high degree of consistency 
in our results with Mitsnefes et al. and Gharis-
vandi et al. studies although the actual amount 
of GFR and its estimated value were applied 
in their studies respectively. Moreover, based 
on our results, it is noticeable that the NGAL 
marker was more powerful compared to 
Cys-C and also had higher accuracy to evalu-
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